Version 1
: Received: 21 September 2023 / Approved: 21 September 2023 / Online: 22 September 2023 (06:26:01 CEST)
Version 2
: Received: 23 November 2023 / Approved: 24 November 2023 / Online: 24 November 2023 (08:41:16 CET)
How to cite:
Ritschl, L.; Schilling, P.; Wittmer, A.; Serr, A.; Schmal, H.; Seidenstuecker, M. Dual Release of Daptomycin and BMP-2 from a Composite of β-TCP Ceramic and ADA Gelatin for Bone Regeneration. Preprints2023, 2023091504. https://doi.org/10.20944/preprints202309.1504.v2
Ritschl, L.; Schilling, P.; Wittmer, A.; Serr, A.; Schmal, H.; Seidenstuecker, M. Dual Release of Daptomycin and BMP-2 from a Composite of β-TCP Ceramic and ADA Gelatin for Bone Regeneration. Preprints 2023, 2023091504. https://doi.org/10.20944/preprints202309.1504.v2
Ritschl, L.; Schilling, P.; Wittmer, A.; Serr, A.; Schmal, H.; Seidenstuecker, M. Dual Release of Daptomycin and BMP-2 from a Composite of β-TCP Ceramic and ADA Gelatin for Bone Regeneration. Preprints2023, 2023091504. https://doi.org/10.20944/preprints202309.1504.v2
APA Style
Ritschl, L., Schilling, P., Wittmer, A., Serr, A., Schmal, H., & Seidenstuecker, M. (2023). Dual Release of Daptomycin and BMP-2 from a Composite of β-TCP Ceramic and ADA Gelatin for Bone Regeneration. Preprints. https://doi.org/10.20944/preprints202309.1504.v2
Chicago/Turabian Style
Ritschl, L., Hagen Schmal and Michael Seidenstuecker. 2023 "Dual Release of Daptomycin and BMP-2 from a Composite of β-TCP Ceramic and ADA Gelatin for Bone Regeneration" Preprints. https://doi.org/10.20944/preprints202309.1504.v2
Abstract
Background: Antibiotic-containing carrier systems are one option that offers the advantage of releasing active ingredients over a longer period of time. In vitro sustained drug release from a carrier system consisting of microporous β-TCP ceramic and alginate has been reported in previous works. Alginate dialdehyde (ADA) gelatin gel showed both better mechanical properties when loaded into a β-TCP ceramic and higher biodegradability than pure alginate. Methods: Dual release of daptomycin and BMP-2 was measured on days 1, 2, 3, 6, 9, 14, 21, and 28 by HPLC and ELISA. After release, the microbial efficacy of the daptomycin was verified and the biocompatibility of the composite was tested in cell culture. Results: Daptomycin and the model compound FITC protein A (n=30) were released from the composite over 28 days. A Daptomycin release above the minimum inhibitory concentration (MIC) by day 9 and a burst release of 71.7 ± 5.9 % were observed in the loaded ceramics. Low concentrations of BMP-2 were released from the loaded ceramics over 28 days.
Keywords
dual release, daptomycin, BMP-2, β-TCP scaffold, ADA-gelatin gel, bone infection, bone regeneration
Subject
Biology and Life Sciences, Life Sciences
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.